Empowering effective biomarker-driven precision oncology: A call to action

• Published in: European journal of cancer (1990) 2024-09, Vol.209, p.114225, Article 114225
• Main Authors: Lawler, Mark, Keeling, Peter, Kholmanskikh, Olga, Minnaard, Warnyta, Moehlig-Zuttermeister, Heike, Normanno, Nicola, Philip, Reena, Popp, Claudia, Salgado, Roberto, Santiago-Walker, Ademi E., Trullas, Ana, van Doorn-Khosrovani, Sahar B. van Waalwijk, Vart, Richard, Vermeulen, Jessica, Vitaloni, Marianna, Verweij, Jaap
• Format: Article
• Language: English
• Subjects: Biomarkers; Comprehensive genomic profiling; Cost effectiveness; In vitro diagnostics; Precision oncology
• ISSN: 0959-8049; 1879-0852; 1879-0852
• DOI: 10.1016/j.ejca.2024.114225

Precision oncology has a significant role to play in delivering optimal patient care. Biomarkers are critical enablers for precision oncology across the continuum of cancer diagnosis, in defining patient prognosis, and in predicting the response to treatments and their potential toxicities, as well as delineating the risk of hereditary cancer syndromes. Biomarkers also potentiate cancer drug development, accelerating patient access to safe and effective therapies. However, despite an accurate and timely diagnosis being critical to patient survival, advances in genomic testing are not being fully exploited in daily clinical practice, leading to missed opportunities to deliver the most effective treatments for patients. Biomarker testing availability and implementation often lag behind approvals of respective biomarker-informed therapies, limiting prompt patient access to these life-saving drugs. Multiple factors currently impede the routine adoption of biomarker testing including, but not limited to, cost, lack of test reimbursement, limited access, regulatory hurdles, lack of knowledge, insufficient cooperation on assay development, and the urgent need to harmonize and validate testing assays, all leading to inefficient diagnostic pathways. Clinical guidelines increasingly include genomic profiling, and recent evidence suggests that precision oncology can be delivered in a cost-effective way for financially-challenged health systems. Therefore, precision genomic testing for cancer biomarkers must be embedded into the clinical practice of oncology care delivery going forward. We articulate a series of recommendations and a call to action to underpin the mainstreaming of a biomarker-informed precision oncology approach to enhance patient outcomes and deliver cost effective 21st century cancer care •Highlighting the importance of biomarkers in accelerating cancer drug discovery.•Identifying and mitigating the factors that impede biomarker adoption.•A series of recommendations and Call To Action to mainstream biomarker-guided clinical care.